STOCK TITAN

Lipocine Inc - LPCN STOCK NEWS

Welcome to our dedicated page for Lipocine news (Ticker: LPCN), a resource for investors and traders seeking the latest updates and insights on Lipocine stock.

Lipocine Inc. (LPCN) is a clinical-stage biopharmaceutical innovator advancing oral therapies for endocrine and central nervous system disorders. This page serves as the definitive source for verified news and press releases related to Lipocine's product pipeline, clinical trials, and strategic developments.

Investors and industry professionals will find timely updates on key initiatives including progress in postpartum depression treatments (LPCN 1154), testosterone replacement therapy (TLANDO), and novel therapies for liver cirrhosis. Our curated news collection provides:

• Clinical trial milestones
• Regulatory updates
• Partnership announcements
• Scientific publications

All content is sourced directly from company filings and authorized communications, ensuring reliability for investment research. Bookmark this page for streamlined access to Lipocine's latest advancements in oral drug delivery technology and therapeutic development.

Rhea-AI Summary

Lipocine (NASDAQ: LPCN) has initiated a Phase 3 trial for LPCN 1154 (oral brexanolone) for treating postpartum depression (PPD). The registration-enabling trial follows successful pharmacokinetic bridge study results showing comparable exposure between LPCN 1154 and the reference drug.

The trial design features a two-arm, randomized, blinded study comparing LPCN 1154 to placebo in women aged 15 and older with severe PPD. Key aspects include:

  • 48-hour at-home self-administration dosing period
  • First patient dosing expected in Q2/2025
  • Primary endpoint: Change from baseline in Hamilton Depression Rating Scale (HAM-D)
  • Secondary endpoints: Changes in Montgomery-Åsberg Depression Rating Scale (MADRS) and Hamilton Anxiety Rating Scale (HAM-A)

The trial aims to support a global registration package for LPCN 1154, potentially positioning it as a first-line option for rapid PPD symptom relief.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.53%
Tags
-
Rhea-AI Summary

Lipocine (NASDAQ: LPCN) reported financial results for 2024, showing a net income of $8,400 compared to a $16.4M loss in 2023. Revenue reached $11.2M, primarily from license agreements with Verity Pharma, SPC Korea, and Pharmalink for TLANDO commercialization.

Key developments include: FDA requiring additional safety and efficacy study for LPCN 1154 (oral brexanolone) for postpartum depression treatment, with Phase 3 study initiation expected in Q2 2025; positive qEEG study data for oral brexanolone; and Fast Track designation for LPCN 1148 for sarcopenia in decompensated cirrhosis patients.

The company maintained strong liquidity with $21.6M in cash and equivalents as of December 31, 2024. R&D expenses decreased to $7.4M from $10.2M in 2023, while G&A expenses remained stable at $5.0M.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.8%
Tags
-
Rhea-AI Summary

Lipocine Inc (NASDAQ: LPCN) announced significant FDA labeling changes for testosterone products following the TRAVERSE clinical trial and post-market blood pressure studies. The FDA has removed the Boxed Warning related to cardiovascular risks from testosterone product labels, while maintaining 'Limitation of Use' language for age-related hypogonadism.

The updated labels will include TRAVERSE trial results and product-specific information on blood pressure effects. These changes are expected to benefit Lipocine's approved testosterone replacement therapy and its development pipeline, which includes candidates for obesity management (LPCN 2401), liver cirrhosis (LPCN 1148), and metabolic dysfunction-associated steatohepatitis (LPCN 1144).

The company has an exclusive license agreement with Verity Pharma since 2024 for marketing rights in the United States and Canada, pending approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.55%
Tags
Rhea-AI Summary

Lipocine (NASDAQ: LPCN) has received updated FDA guidance for LPCN 1154, its postpartum depression (PPD) treatment candidate. The FDA has indicated that beyond the previously completed PK bridge data, an additional efficacy and safety study in the target population will be required for 505(b)(2) NDA submission.

Following comparable exposure results between LPCN 1154 and the reference drug in the completed PK bridge study, Lipocine is planning to proceed with a phase 3 safety and efficacy study. The company views this requirement as an opportunity to generate valuable safety and depression symptom relief data for product labeling and potential clinical investigation exclusivity for a 48-hour, oral treatment option. Additionally, the planned study will explore oral brexanolone's potential in treating anxiety disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.67%
Tags
none
-
Rhea-AI Summary

Lipocine (NASDAQ: LPCN) has received Fast Track Designation from the FDA for LPCN 1148, targeting sarcopenia treatment in patients with decompensated cirrhosis. The designation follows positive results from a Phase 2 proof-of-concept study where LPCN 1148, an oral prodrug of bioidentical testosterone, demonstrated improvements in sarcopenia and associated clinical outcomes.

LPCN 1148 aims to be a 'First in Class' treatment where no current therapy exists. The Fast Track status enables benefits including more frequent FDA meetings, enhanced communication about clinical trial design, eligibility for Accelerated Approval and Priority Review, and Rolling Review submission options for the New Drug Application (NDA).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.41%
Tags
-
Rhea-AI Summary

Lipocine announced the publication of LPCN 1148's Phase 2 clinical trial results in Hepatology journal and its discussion at The Liver Meeting 2024. The study evaluated LPCN 1148 in men with cirrhosis and sarcopenia awaiting liver transplantation. At 24 weeks, LPCN 1148 showed significant improvement in sarcopenia compared to placebo and resulted in fewer episodes of overt hepatic encephalopathy (OHE), despite patients being on background therapies. The treatment also demonstrated beneficial effects on muscle quality, hemoglobin, and patient-reported symptoms. LPCN 1148 is positioned as a potential 'First in Class' product for OHE and sarcopenia indications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.48%
Tags
none
Rhea-AI Summary

Lipocine Inc (NASDAQ: LPCN) reported Q3 2024 financial results with a net loss of $2.2 million ($0.44 per share), compared to a $6.7 million loss in Q3 2023. The company had $19.8 million in cash and equivalents as of September 30, 2024. Key developments include positive results from LPCN 1154's qEEG study for postpartum depression treatment, with NDA submission targeted for end of 2024. Lipocine signed exclusive distribution agreements for TLANDO in GCC countries and South Korea. For the nine months ended September 30, 2024, revenue was $7.7 million, primarily from licensing, with a net loss of $1.8 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.76%
Tags
-
Rhea-AI Summary

Lipocine Inc. (NASDAQ: LPCN) has entered into a license, development and supply agreement with SPC Korea for exclusive marketing rights of TLANDO® in South Korea. The agreement includes an upfront payment, potential regulatory and sales milestone payments, royalties on net commercial sales, and a supply price arrangement. SPC Korea will be responsible for obtaining regulatory approval in South Korea. This partnership aims to expand TLANDO's global reach and address unmet medical needs in the South Korean market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.57%
Tags
none
-
Rhea-AI Summary

Lipocine Inc. (NASDAQ: LPCN) announced positive data from its quantitative Electroencephalogram (qEEG) study of oral brexanolone, a neuroactive steroid being developed for post-partum depression (PPD). The study, conducted on 12 healthy postmenopausal females, showed robust central nervous system (CNS) activity with concentration- and time-dependent post-dose changes in qEEG.

Key findings include:

  • Significant increases in theta and alpha1 band power in posterior cortical regions
  • Decrease in alpha2 band power
  • Considerable beta band amplitude increase across all cortical brain areas
  • Rapid onset of effects (as early as 2 hours) with maximum impact at 4 hours post-dose
  • Effects lasting up to 12 hours post-dose

These results confirm GABAA positive allosteric modulation and support the potential utility of oral brexanolone in treating various neuropsychiatric indications, including depression, anxiety, essential tremor, and epilepsy. The safety profile was consistent with previous clinical studies, showing minimal CNS depressant effects.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.58%
Tags
none
Rhea-AI Summary

Lipocine Inc. (NASDAQ: LPCN) has announced an exclusive supply and distribution agreement with Pharmalink to commercialize TLANDO®, its oral testosterone replacement therapy, in the Gulf Cooperation Council (GCC) countries. The agreement covers Saudi Arabia, Kuwait, the United Arab Emirates, Qatar, Bahrain, and Oman.

Under the terms of the agreement, Lipocine received an upfront payment from Pharmalink. Upon obtaining Marketing Authorizations in individual GCC countries, Lipocine will provide TLANDO drug product to Pharmalink at an agreed transfer price. Pharmalink will have exclusive rights to TLANDO in the GCC region and will be responsible for promotion, distribution, and sale of the product in the territory.

This partnership aligns with Lipocine's global strategy to expand the availability of TLANDO and make it broadly accessible. Pharmalink's expertise and established network in the GCC region make them an ideal partner to support the adoption and growth of TLANDO in these markets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.21%
Tags
none
Lipocine Inc

Nasdaq:LPCN

LPCN Rankings

LPCN Stock Data

16.10M
5.19M
2.9%
9.16%
1.43%
Biotechnology
Pharmaceutical Preparations
Link
United States
SALT LAKE CITY